Evidence map›Paper›PMID 42728553›Full record

ArticleAnnals of surgical oncology2026

Glypican 3-Targeted Fluorescent Imaging for Intraoperative Tumor Boundary Identification in Hepatocellular Carcinoma.

Shuhei Kanda, Hiroto Nishino, Tomoaki Yoh, Keisuke Okura, Makoto Kurimoto, Yutaro Hori, Takahiro Nishio, Keiko Iwaisako, Satoshi Ogiso, Etsuro Hatano

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuhei KandaDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiroto NishinoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. hnishino@kuhp.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0002-7377-9997
Tomoaki YohDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Keisuke OkuraDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Makoto KurimotoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yutaro HoriDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Takahiro NishioDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Keiko IwaisakoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Satoshi OgisoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Etsuro HatanoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Funding

Japan Society for the Promotion of Science KAKENHI 23K15448
6 · The paper itself

Abstract

backgroundIntraoperative tumor boundary identification is essential for complete resection of hepatocellular carcinoma (HCC). Glypican-3 (GPC3) is a tumor-associated membrane antigen that is highly expressed in most HCCs but barely in livers. This study evaluated the feasibility of GPC3 as a tumor-specific imaging target and developed a GPC3-targeted fluorescent probe for intraoperative tumor boundary identification. PATIENTS AND

methodsIn the clinical study, intraoperative tumor identification using indocyanine green (ICG) fluorescence was evaluated in 38 patients with HCC, and clinicopathological factors were compared between identifiable and nonidentifiable groups. The tumor specificity of GPC3 was validated by immunohistochemistry of resected specimens. In the experimental study, a GPC3-targeted probe (GPC3-IRDye800) was developed and administered to human HCC cell-line-derived mouse models. Antigen specificity and tumor boundary identifiability were assessed in vivo and ex vivo. Fluorescence-guided surgery (FGS) was performed to examine the feasibility of complete resection.

resultsICG enabled tumor identification in 30 patients (78.9%). Cirrhosis was significantly associated with detection failure. GPC3 expression was observed in 35 tumors (92.1%) and was higher in the tumors than in the peritumoral livers (P < 0.0001). GPC3-IRDye800 demonstrated antigen-dependent uptake, with higher fluorescence intensity and tumor-to-background ratios than controls (P < 0.0001). At 72 h post-administration in both normal- and fibrotic-liver mouse models, GPC3-IRDye800 provided higher fluorescence intensity at the tumor boundary than ICG. FGS using this probe allowed for complete tumor resection without margin exposure.

conclusionsGPC3-IRDye800 enables reliable tumor boundary visualization, regardless of background liver condition, and may contribute to complete tumor resection.

Indexed as

Fluorescence-guided surgeryFluorescent antibodyGlypican-3Hepatocellular carcinomaLiver fibrosisMouse modelTumor boundaryTumor targeting

Identifiers

PMID42728553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.